Eisai Co., Ltd. (ESAIY) Stock Price & Analysis
Eisai Co., Ltd. (ESAIY) — price $7.41 (-0.54%), as of the Oct 5, 2026 trading session; market cap $8.32B.
Educational signal · not a buy or sell recommendation · How to read this
Eisai Co., Ltd. · ESAIY · Healthcare · Drug Manufacturers - Specialty & Generic
Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan.
Price as of Oct 5, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $7.41 | |
| Change on the day | -0.54% | |
| 52-week range | $5.69–$8.58 | |
| Market capitalisation | $8.32B | |
| Price / earnings (trailing) | 31.14 | |
| Shares traded on the day | 13.4K | |
| Beta (volatility vs the S&P 500) | -0.07 | |
| Dividends per share (last 12 months) | $0.13 | |
| Dividend yield (last 12 months) | 1.74% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results
- · Earnings results
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Regarding LEQEMBI, regarding your point about LEQEMBI, we still have the second, third and fourth quarter where we expect to see further increase of the revenue for LEQEMBI.
Takuya Oyama · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations can change.
Read management statementsOther perspectives
Council score for Eisai Co. (ESAIY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ESAIY film — every key number, told as a short cinematic story
~2 min · open the film
What is Eisai Co. (ESAIY), and what does it report?
Short answer · as of
Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. Healthcare / Drug Manufacturers Specialty & Generic Headquarters: 4-6-10, Koishikawa, Tokyo, TY, 112-8088, JP. It employs 10,543 people and is led by Haruo Naito. In Q1 FY2026 it reported revenue of $1.50B and net income of $117M. The market values it at $8.32B.
What do the latest results show for Eisai Co. (ESAIY)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $1.50B.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.31B May 13, 2026
- Latest report · revenue estimate
- $195.68B May 13, 2026
- Latest report · revenue vs estimate
- Below estimate May 13, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| May 13, 2026 | $1.31B | $195.68B | −$0.0184 | Not available |
| Feb 5, 2026 | $1.43B | $212.26B | $0.0989 | Not available |
| Nov 6, 2025 | $1.34B | $197.61B | $0.0610 | $0.0691 |
| Aug 4, 2025 | $1.41B | $197.60B | $0.0900 | $0.0596 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $1.50B | $117M | $0.10 (diluted) |
| Q4 FY2025 | $1.32B | -$21M | -$0.02 (diluted) |
| Q3 FY2025 | $1.42B | $111M | $0.10 (diluted) |
| Q2 FY2025 | $1.27B | $65M | $0.06 (diluted) |
What are the financial strengths and risks for Eisai Co. (ESAIY)?
Short answer
The distress and quality screens read Altman Z 2.79 · Piotroski F 6. Trailing ratios: ROE 4.8% · ROA 2.7% · current ratio 2.24 · earnings yield 3.1% · free-cash-flow yield 3.1%.
What should you watch next at Eisai Co. (ESAIY)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $911.13B · EPS 53.23 · 7 analysts.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Regarding LEQEMBI, regarding your point about LEQEMBI, we still have the second, third and fourth quarter where we expect to see further increase of the revenue for LEQEMBI.
Takuya Oyama ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $911.13B
- EPS estimate
- $53.23
Measured against a quoted price of $7.41 (as of Oct 5, 2026).
What Investors Ask About Eisai Co. (ESAIY) — Healthcare
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does Lenvima fit into Eisai's business?
Lenvima is a molecularly targeted oncology medicine used across several cancer settings, including combination treatment. It sits within an established oncology portfolio that also includes Halaven and a partnered antibody-drug conjugate program with Bristol Myers Squibb.
What is the ESAIY stock price today?
The last price recorded on this page for Eisai Co., Ltd. (ESAIY) is $7.41, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does ESAIY pay a dividend?
Yes. Eisai Co., Ltd. (ESAIY) shows a trailing 12-month dividend yield of 1.74%, as of Oct 5, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (40 figures)
The 40 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Takuya Oyama (Aug 3, 2026): Regarding LEQEMBI, regarding your point about LEQEMBI, we still have the second, third and fourth quarter where we expect to see further increase of the revenue for LEQEMBI. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 30 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $7.41 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:54:42.739Z. | |
px.change | Change on the day | -0.54% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $8.32B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-05. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.04 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $5.69–$8.58 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 31.14 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 13.4K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | -0.07 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers Specialty & Generic | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | 4-6-10, Koishikawa, Tokyo, TY, 112-8088, JP | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 10,543 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Haruo Naito | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q1 FY2026 | $1.50B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q1 FY2026 | $117M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-05-13.revenue_actual | Revenue · reported — report date 2026-05-13 | $1.31B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.revenue_estimated | Revenue · estimate — report date 2026-05-13 | $195.68B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.eps_actual | EPS · reported — report date 2026-05-13 | −$0.0184 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_actual | Revenue · reported — report date 2026-02-05 | $1.43B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_estimated | Revenue · estimate — report date 2026-02-05 | $212.26B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_actual | EPS · reported — report date 2026-02-05 | $0.0989 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.revenue_actual | Revenue · reported — report date 2025-11-06 | $1.34B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.revenue_estimated | Revenue · estimate — report date 2025-11-06 | $197.61B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_actual | EPS · reported — report date 2025-11-06 | $0.0610 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_estimated | EPS · estimate — report date 2025-11-06 | $0.0691 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-04.revenue_actual | Revenue · reported — report date 2025-08-04 | $1.41B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-04.revenue_estimated | Revenue · estimate — report date 2025-08-04 | $197.60B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-04.eps_actual | EPS · reported — report date 2025-08-04 | $0.0900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-04.eps_estimated | EPS · estimate — report date 2025-08-04 | $0.0596 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z 2.79 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 4.8% · ROA 2.7% · current ratio 2.24 · earnings yield 3.1% · free-cash-flow yield 3.1% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2027 revenue $911.13B · EPS 53.23 · 7 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-08-24 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2027 | $911.13B | UNRECORDED | Stored analyst estimates — Captured 2026-08-24 · Expired observation | |
earn.est_eps | EPS estimate, FY2027 | $53.23 | UNRECORDED | Stored analyst estimates — Captured 2026-08-24 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.13 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 1.74% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-05-13.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.31B) with the recorded estimate ($195.68B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-05-13. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-05-13.revenue_actual,earn.history.depth.2026-05-13.revenue_estimated,earn.history.depth.2026-05-13.revenue_actual.comparison,earn.history.depth.2026-05-13.eps_actual,earn.history.depth.2026-02-05.revenue_actual,earn.history.depth.2026-02-05.revenue_estimated,earn.history.depth.2026-02-05.eps_actual,earn.history.depth.2025-11-06.revenue_actual,earn.history.depth.2025-11-06.revenue_estimated,earn.history.depth.2025-11-06.eps_actual,earn.history.depth.2025-11-06.eps_estimated,earn.history.depth.2025-08-04.revenue_actual,earn.history.depth.2025-08-04.revenue_estimated,earn.history.depth.2025-08-04.eps_actual,earn.history.depth.2025-08-04.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. Its comprehensive product portfolio includes prominent medications such as Dayvigo, prescribed for insomnia, and the potent anticancer drug Lenvima, a molecularly targeted therapy effective against thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma when paired with everolimus. The company also markets Methycobal for peripheral neuropathy and Halaven, another anticancer agent targeting breast cancer. Further offerings encompass Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid formulation; Goofice and Movicol, utilized for managing chronic constipation; Fycompa, an antiepileptic; Pariet, a proton-pump inhibitor; and Aricept, a treatment for Alzheimer's and Dementia with Lewy bodies. Additionally, it produces Chocola BB plus, a vitamin B2 supplement. Eisai maintains a strategic alliance with Bristol Myers Squibb, focusing on the joint development and commercialization of the antibody drug conjugate, farletuzumab ecteribulin. Established in Tokyo, Japan, in 1941, the company was initially known as Nihon Eisai Co., Ltd. before adopting its current name, Eisai Co., Ltd., in 1955. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.